Tessera Therapeutics Inc. has received a grant from the Gates Foundation to support early-stage research exploring multiple genetic approaches aimed at developing a scalable cure for HIV. This research will evaluate several potential strategies leveraging Tessera’s Gene Writing platform to engineer immune cells in vivo.

KSP-1007 is a new bicyclic boronate-based broad-spectrum β-lactamase inhibitor that, in combination with meropenem, is under development for the treatment of infections caused by carbapenem-resistant gram-negative bacteria that produce serine- and metallo-type carbapenemases.

Aptar Pharma, part of Aptargroup Inc., has established a technical collaboration with Covirix Medical Pty Ltd. under a letter of intent to develop inhaled antiviral treatments.

Atea Pharmaceuticals Inc. recently presented preclinical data on two of its compounds, AT-2490 and AT-587, which have shown promising antiviral potential for treating hepatitis E virus infection.

Aiming to develop a vaccine candidate against human adenovirus-55 (HAdV-55) infections, researchers from the First Affiliated Hospital of Guangzhou Medical University (China) and collaborators have generated a replication-incompetent rAd55-5E4.

HIV-1 persistence in latent reservoirs of T lymphoid and myeloid origin is a major barrier for the cure of the disease, with complex and multifactorial mechanisms behind HIV-1 latency; thus, investigating these mechanisms is key for future targeted HIV therapies.

Gilead Sciences Inc.’s integrase strand transfer inhibitor (INSTI) GS-3242 is in early clinical development for HIV infection (NCT07001319). The company presented nonclinical data on the candidate at the recent CROI meeting in Denver.

CARB-X is awarding $1.2 million to the Andrew G. Myers research group at Harvard University to develop enhanced antibiotics that target multidrug-resistant gram-negative bacterial pathogens, including Escherichia coli and Klebsiella pneumoniae, to treat urinary tract infections, pneumonia and bloodstream infections.